. 2020 May 18;40(7):1713–1724. doi: 10.1111/liv.14498

Table 4.

Diagnostic accuracy of enhanced liver fibrosis (ELF) score and vibration‐controlled transient elastography (VCTE) for clinically significant portal hypertension (CSPH) and high‐risk portal hypertension (HRPH)

	AUROC	95%CI	P‐value	Cut‐off	SENS	SPEC	PPV	NPV	PLR	NLR
CSPH—Overall cohort
ELF	0.833	0.75‐0.92	<.001	Youden: 10.5	0.81	0.75	0.96	0.35	3.24	0.25
				In: 11.1	0.61	0.92	0.98	0.24	7.63	0.42
				Out: 9.7	0.97	0.38	0.92	0.6	1.56	0.08
TE ^a	0.834	0.76‐0.91	<.001	Youden: 23.2	0.70	0.95	0.99	0.36	14.8	0.31
				In: 23.2	0.70	0.95	0.99	0.36	14.8	0.31
				Out: 11.8	0.95	0.29	0.88	0.5	1.33	0.18
CSPH—ALD
ELF	0.978	0.94‐1.00	.001	Youden: 10.3	0.95	1	1	0.5	—	0.05
				In: 10.3	0.95	1	1	0.5	—	0.05
				Out: 9.9	0.99	0.5	0.98	0.67	1.98	0.02
CSPH—VIRAL
ELF	0.629	0.42‐0.84	0.265	—	—	—	—	—	—	—
CSPH—cACLD
ELF	0.759	0.64‐0.87	<.001	Youden: 10.5	0.69	0.78	0.90	0.49	3.14	0.4
				In: 11.1	0.42	0.91	0.93	0.37	4.67	0.64
				Out: 9.6	0.97	0.26	0.78	0.75	1.31	0.12
TE ^a	0.743	0.62‐0.86	.002	Youden: 23.2	0.59	0.95	0.95	0.5	11.7	0.43
				In: 23.2	0.59	0.95	0.95	0.5	11.7	0.43
				Out: 11.8	0.89	0.30	0.75	0.55	1.27	0.36
HRPH—Overall cohort
ELF	0.677	0.60‐0.75	<.001	Youden: 11.1	0.75	0.56	0.45	0.83	1.70	0.45
				In: 13.0	0.18	0.9	0.48	0.7	1.80	0.91
				Out: 10.1	0.97	0.26	0.39	0.95	1.31	0.12
TE ^a	0.813	0.74‐0.89	<.001	Youden: 27.4	0.92	0.59	0.45	0.95	2.23	0.14
				In: 67.1	0.43	0.91	0.64	0.82	4.9	0.62
				Out: 27.4	0.92	0.59	0.45	0.95	2.23	0.14

Abbreviations: 95%CI, 95% confidence interval; ALD, alcohol‐related liver disease; AUROC, area under the receiver operating characteristics; cACLD, compensated advanced chronic liver disease; CSPH, Clinically significant portal hypertension; ELF, enhanced liver fibrosis score; HRPH, high‐risk portal hypertension; NLR, negative likelihood ratio; PLR, positive likelihood ratio; VCTE, vibration‐controlled transient elastography.

P‐values < .05, PPV and NPV ≥ 0.90, PLR > 7 and NRL < 0.1 are indicated in bold.

^{^a}

Reliable VCTE results available in n = 139 (69.2%) patients in the overall cohort, and n = 66 (77.6%) patients with cACLD.